Search
Tislelizumab
go.drugbank.com/drugs/DB14922ApprovedInvestigational[L49439] Tislelizumab was also approved by the FDA on March 14, 2024.[L50346] It has subsequently been approved for additional cancers in the US and EU. [L49349] … [A262909] By blocking PD-L1/PD-L2–mediated cell signaling, tislelizumab restores T-cell function through cytokine production, resulting in immune-mediated antitumor responses.
Atrasentan
go.drugbank.com/drugs/DB06199ApprovedInvestigationalto be approved for this condition. … [L52855] In April 2025, atrasentan was granted accelerated approval by the FDA for the reduction of proteinuria in patients with primary IgA nephropathy, becoming the first endothelin A receptor antagonist
Finerenone
go.drugbank.com/drugs/DB16165ApprovedInvestigational[A236544,L34739] Finerenone was granted FDA approval on 9 July 2021,[L34739] followed by the EMA approval on 11 March 2022.[L41449] … Finerenone, or BAY 94-8862, is a mineralocorticoid receptor antagonist indicated to reduce the risk of sustained decline in glomerular filtration rate, end stage kidney disease, cardiovascular death, heart
Darvadstrocel
go.drugbank.com/drugs/DB16581ApprovedInvestigationalWithdrawn[A244524] Darvadstrocel was first approved by the European Commission on March 23, 2018, under the brand name Alofisel. … It is indicated for the treatment of complex perianal fistulas in adult patients with non-active or mildly active luminal Crohn’s disease when fistulas have shown an inadequate response to at least one
Aripiprazole
go.drugbank.com/drugs/DB01238ApprovedInvestigational[L45859,A4393] Aripiprazole was given FDA approval on November 15, 2002.[L6136]
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeProducts: Nb-aripiprazoleAliskiren
go.drugbank.com/drugs/DB09026ApprovedInvestigational[A203624] It was developed by Speedel and Novartis and initially approved by the FDA in early 2007. … [L14018] Aliskiren has been proven to efficacious in reducing blood pressure when used alone or in conjunction with other antihypertensive agents.[A203624]
Categories: Agents Acting on the Renin-Angiotensin SystemLanthanum carbonate
go.drugbank.com/drugs/DB06792ApprovedIt is used to treat elevated phosphate levels, primarily in patients with chronic kidney disease, by binding to dietary phosphate and preventing its absorption in the intestine.[L50733] … Lanthanum carbonate is a phosphate binder marketed under the trade name _Fosrenol_ by Shire Pharmaceuticals.
Homatropine methylbromide
go.drugbank.com/drugs/DB00725ApprovedIt may also be used to prevent nausea, vomiting, and motion sickness. … Homatropine methylbromide is a quaternary ammonium muscarinic acetylcholine receptor antagonist belonging to the group of medicines called anti-muscarinics.
Mixtures: BONESPAS GOTAS COMPOSITE NFBimatoprost
go.drugbank.com/drugs/DB00905ApprovedInvestigationalBimatoprost, marketed by Allergan, is administered in both the ophthalmic solution and implant form. … [L6910] It was initially approved by the FDA in 2001 for ocular hypertension and later approved for hypothrichosis in 2008, as eyelash growth became a desirable adverse effect for patients using this drug
Synonyms: (Z)-7-((1R,2R,3R,5S)-3,5-Dihydroxy-2-((1E,3S)-3-hydroxy-5-phenyl-1-pentenyl)cyclopentyl)-N-ethyl-5-heptenamideBemotrizinol
go.drugbank.com/drugs/DB11206ApprovedCompared to older broad-spectrum chemical agents, bemotrizinol is more more fat soluble (oil soluble in cosmetic oils) to aid in efficacy and broad-spectrum activity [A19212]. … It is claimed to be photostable, which increases its onset of action and its efficiency in providing protection against UV-rays upon topical application [A19212, A32909].
Mixtures: Dpc Pink Aura Cushion No.21, Dpc Pink Aura Cushion No.23